Disclaimer
We’re actively expanding Guideline Genius to cover the full UKMLA content map. You may notice some conditions not uploaded yet, or articles that only include diagnosis and management for now. For updates, follow us on Instagram @guidelinegenius.
We openly welcome any feedback or suggestions through the anonymous feedback box at the bottom of every article and we’ll do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

Total Live Articles: 312

Venous Thromboembolism (DVT and PE)

NICE guideline [NG158] Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. Last updated: Aug 2023.

Background information

Definition

Venous thromboembolism (VTE): is a term that encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE).

  • Deep vein thrombosis: clot formation (thrombosis) within a deep vein; most commonly of the legs or pelvis.
  • Pulmonary embolism: life threatening condition characterised by the presence of emboli, usully arising from a DVT, in the pulmonary arterial system.

Provoked DVT/PE (~2/3 of cases): occuring in the presence of a recent (within 3 months) major clinical risk factor for VTE

Unprovoked DVT/PE (~1/3 of cases): occuring in the absence of a recent (within 3 months) major clinical risk factor for VTE

Whether VTE is provoked/unprovoked plays a role in the duration of anticoagulation on NICE guidelines

Epidemiology

  • Common; VTE is the third most common cardiovascular disease (after acute myocardial infarction & stroke)
    • VTE cases
      • 1/3 → PE
      • 2/3 → DVT
    • Incidence increases sharply with age / presence of risk factors

 

Aetiology

Deep Vein Thrombosis

DVT is caused by risk factors that fall under Virchow’s triad 

Virchow’s triad encompasses the 3 major mechanisms that cause thrombosis

  1. Hypercoagulability
  2. Endothelial / vessel wall damage
  3. Venous stasis

Risk factors for DVT grouped by Virchow’s triad 

1. Hypercoagulability 

  • Personal / family history of VTE
  • Active cancer
  • Pregnancy / Puerperium
  • Hormone therapy (COCP / HRT)
  • APS / thrombophilias (familial/acquired)
  • Inflammatory, pro-thrombotic disorders
  • Diabetes mellitus
  • Smoking
  • Male sex (particularly for DVT)
  • Dehydration

2. Endothelial damage

  • Recent trauma or lower limb fracture
  • Surgery (direct vessel trauma) – esp major surgeries
  • Direct venous trauma (e.g. IV cannula, indwelling central venous catheter)
  • Recent myocardial infarction (< 3 months)
  • Varicose veins / Superficial venous thrombosis

 

3. Venous stasis

  • Significant immobility / hospitalisation / bed rest >5 days
  • Prolonged travel (> 4 hours)
  • Heart failure
  • Obesity (BMI >30)
  • Increasing age (↑ incidence / mortality)

Pulmonary Embolism

Most common cause → DVT

Other → causes of nonthrombotic embolism:

  • Fat embolism
  • Air embolism
  • Amniotic fluid embolism
  • Septic/Bacterial embolism

Clinical features

Deep Vein Thrombosis

Localisation → DVT is typically unilateral 

Symptoms

  • Leg pain / tenderness 
    • Throbbing, cramping or dull ache
    • Worse on walking/weight bearing
  • Swelling (often calf or thigh)
    • Feeling of tightness or heaviness
  • Systemic features
    • Low-grade fever, malaise
  • If concurrent → symptoms of pulmonary embolism (e.g., dyspnoea, chest pain)

Signs / Examination Findings 

  • Leg swelling 
    • Calf-circumference difference
    • Pitting oedema
  • Erythema → redness, warmth or livid discoloration
  • Dilated superficial veins 
  • Local tenderness on palpation
  • Special tests (less reliable, non-diagnostic but often mentioned)
    • Homans sign → calf pain on foot dorsiflexion
    • Meyer sign (calf-squeeze) → calf pain on compression

 

Pulmonary Embolism

Symptoms

  • Onset → typically sudden
  • Dyspnoea → most common symptom (~50% of cases)
    • Typically persistent or progressive
  • Pleuritic chest pain (~40% of cases) OR retrosternal chest pain (less common)
  • Cough ± haemoptysis
  • Syncope or pre-syncope → more in massive PE
  • Systemic features (fever, dizziness, weakness)
  • Symptoms of DVT may be present

Signs / Examination findings 

  • General comments
    • Signs / Examination findings are often nonspecific.
    • Many patients have a normal physical examination (esp in smaller emboli)
  • Potential findings 
    • Observations
      • Tachypnoea / Tachycardia (common) 
      • Hypoxia 
      • Fever (uncommon, typically low-grade)
      • Hypotension / shock → suggests massive PE
    • Right heart strain 
      • Elevated JVP
      • Heart auscultation → loud P2, widely split S2
    • Pleural rub

Complications

Deep Vein Thrombosis

  • Pulmonary embolism

 

  • Recurrent DVT

 

  • Post-thrombotic syndrome (PTS)  → up to 50% within 2 years of lower limb DVT
    • Definition → ​​​chronic venous insufficiency in the affected limb, secondary to DVT
    • Clinical Dx → symptoms of chronic venous insufficiency (e.g., limp pain, swelling, oedema, skin hyperpigmenation), typically, 3-6 months after initial DVT event

 

Pulmonary Embolism

  • Acute
    • Arrythmias
    • Respiratory failure
    • Right ventricular failure ± haemodynamic instability
    • Sudden cardiac death (often due to PEA)

 

  • Chronic 
    • Chronic thromboembolic pulmonary hypertension (CTEPH)
      • Rare & severe complication (progresses to right heart failure)
      • Subtype of pulmonary hypertension caused by chronic thromboembolic occlusion of pulmonary vessels

 

Deep Vein Thrombosis Guidelines

Assessment and Management Algorithm

If DVT is suspected, calculate the two-level DVT Wells score

Clinical feature Points
Active cancer (or within 6 months) 1
Lower limb immobilisation (recent plaster use, paralysis, paresis) 1
Recently bedridden for ≥3 days or major surgery within 12 weeks requiring general or regional anaesthesia 1
Localised tenderness along the distribution of deep venous system 1
Entire leg swollen 1
Calf swelling >3 cm larger than the other leg 1
Pitting oedema confined to the affected leg 1
Collateral superficial veins (non-varicose) 1
Previously documented DVT 1
An alternative diagnosis is at least as likely as DVT -2

Interpretation:

  • Score 2 or more: DVT likely
  • Score 1 or less: DVT unlikely

 

DVT Likely (Wells 2 or more)

Perform a proximal leg vein ultrasound (with results available within 4 hours)

 

If the ultrasound cannot be done within 4 hours, perform the following:

  • Perform D-dimer test, and
  • Offer interim therapeutic anticoagulation, and
  • Ensure ultrasound is done within 24 hours

Abnormal Ultrasound

Diagnose DVT and start treatment

Normal Ultrasound

Perform D-dimer test

  • -ve D-dimer → DVT unlikely, consider alternative diagnosis (stop any interim anticoagulation)

 

  • +ve D-dimer → repeat proximal leg vein ultrasound 6-8 days later (stop any interim anticoagulation)
    • Abnormal ultrasound → start treatment
    • Normal ultrasound → consider alternative diagnosis

A single negative proximal ultrasound does not definitively exclude DVT in patients with high clinical suspicion or elevated D-dimer.

Anticoagulation (e.g., apixaban) should not be continued unless DVT is confirmed, due to bleeding risk and lack of proven benefit in the absence of objective evidence of thrombosis

DVT Unlikely (Wells 1 or less)

Perform D-dimer test (with results available within 4 hours):

  • -ve D-dimer → DVT unlikely, consider alternative diagnosis (stop any interim anticoagulation)
  • +ve D-dimer → perform a proximal leg vein ultrasound (with results available within 4 hours)
    • If ultrasound not possible → offer interim therapeutic anticoagulation and ensure ultrasound is done within 24 hours

 

If D-dimer cannot be done within 4 hours → offer interim therapeutic anticoagulation while waiting

Treatment For Confirmed DVT

This section is identical for DVT and PE

The drug class of choice to treat DVT and PE are anticoagulants.

Choice of Drug

1st line:

  • Apixaban or rivaroxaban

2nd line:

  • Warfarin with LMWH lead-in, or
  • Dabigatran or edoxaban with LMWH lead-in

 

In renal impairment (not renal failure), apixaban is preferred over rivaroxaban as it has less renal excretion​​​​​​.

Choice of Drug in Specific Patient Populations

Patient population Recommended drug
Renal failure (creatinine clearance <15 mL/min) Avoid DOAC, use:
  • LMWH, or
  • UFH, or
  • Warfarin
Active cancer
  • 1st line: DOAC
  • 2nd line: LMWH
Pregnancy DOAC and warfarin are contraindicated, use:
  • LMWH, or
  • UFH
Anticoagulation contraindicated Consider inferior vena cava filter
Antiphospholipid syndrome (triple positive) Warfarin with LMWH lead-in

Duration of Treatment

  • Provoked: 3 months
  • Unprovoked: 6 months
  • Concurrent cancer: 3-6 months

Pulmonary Embolism (PE) Guidelines

Assessment and Management Algorithm

If PE is suspected, calculate the two-level PE Wells score

Clinical feature Points
Clinical features of DVT (minimum of leg swelling and pain with palpation of the deep veins) 3
An alternative diagnosis is less likely than PE 3
Heart rate >100 bpm 1.5
Immobilisation for >3 days or surgery in the previous 4 weeks 1.5
Previous DVT / PE 1.5
Haemoptysis 1
Active cancer (or within 6 months) 1

Interpretation:

  • Score 5 or more: PE likely
  • Score 4 or less: PE unlikely

 

PE Likely (Wells 5 or more)

Perform a CT pulmonary angiogram (CTPA) immediately

  • Abnormal CTPA → diagnose PE and start treatment
  • Normal CTPA
    • If DVT is suspected → consider a proximal leg vein ultrasound scan
    • If DVT is not suspected → PE unlikely, consider alternative diagnosis (stop any interim anticoagulation)

 

If CTPA is not appropriate (allergic to contrast / severe renal impairment – creatinine clearance <30 mL/min / high risk from irradiation)

  • Consider V/Q SPECT or planar scan as an alternative

 

If CTPA / V/Q scan cannot be done immediately → offer interim therapeutic anticoagulation while awaiting CTPA

Bedside echocardiography to assess right ventricular strain is an appropriate alternative in those who are not suitable candidates for CTPA (e.g. clinically unstable for imaging, allergic to contrast, severe renal impairment, high risk from irradiation).

Note that this is not mentioned in NICE guidelines but is commonly performed in practice, and endorsed by international echocardiography guidelines.

PE Unlikely (Wells 4 or less)

Perform D-dimer test (with results available within 4 hours):

  • -ve D-dimer → PE unlikely, consider alternative diagnosis (stop any interim anticoagulation)
  • +ve D-dimer → perform CTPA (or V/Q scan) immediately (i.e. follow the above PE likely algorithm)

 

If D-dimer cannot be done within 4 hours → offer interim therapeutic anticoagulation while waiting

Bedside echocardiography to assess right ventricular strain is an appropriate alternative in those who are not suitable candidates for CTPA (e.g. clinically unstable for imaging, allergic to contrast, severe renal impairment, high risk from irradiation).

Note that this is not mentioned in NICE guidelines but is commonly performed in practice, and endorsed by international echocardiography guidelines.

PE with Haemodynamic Instability

Hemodynamic instability is indicated by any of the following: [Ref]

  • Hypotension (SBP <90 mmHg, or >40 mmHg drop that are not explained by other causes)
  • End-organ hypoperfusion (features inc. altered mental status, cold/clammy skin, oliguria, or elevated lactate)
  • Cardiac arrest

This clinical scenario is also termed “high-risk” or “massive” pulmonary embolism

Offer Immediate Reperfusion Therapy:

  • Continuous UFH infusion, and
  • Consider thrombolytic therapy (e.g. alteplase)

The presence of right ventricular dysfunction (confirmed on echocardiography & supported by elevated cardiac biomarkers) is NOT an indication for thrombolysis by itself (unless there is hemodynamic instability).

Treatment For Confirmed PE

This section is identical for DVT and PE

The drug class of choice to treat DVT and PE are anticoagulants.

Choice of Drug

1st line:

  • Apixaban or rivaroxaban

2nd line:

  • Warfarin with LMWH lead in, or
  • Dabigatran or edoxaban with LMWH lead in

 

Choice of Drug in Specific Patient Populations

Patient population Recommended drug
Renal failure (creatinine clearance <15 mL/min) Avoid DOAC, use:
  • LMWH, or
  • UFH, or
  • Warfarin
Active cancer
  • 1st line: DOAC
  • 2nd line: LMWH
Pregnancy DOAC and warfarin are contraindicated, use:
  • LMWH, or
  • UFH
Anticoagulation contraindicated, or PE happened while on anticoagulation Consider inferior vena cava filter
Antiphospholipid syndrome (triple positive) Warfarin with LMWH lead in

Duration of Treatment

  • Provoked: 3 months
  • Unprovoked: 6 months
  • Concurrent cancer: 3-6 months

References

NICE Algorithm – DVT Diagnosis and Initial Management

NICE Algorithm – PE Diagnosis and Initial Management

NICE Visual Aid – Anticoagulation in DVT and PE

Original Guideline

Share Your Feedback Below

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD